HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors by Ahmed Nabil, Salsman Vita S, Kew Yvonne, Shaffer Donald, Powell Suzanne, Zhang Yi J, Grossman Robert G, Heslop Helen E, Gottschalk Stephen in Clinical cancer research : an official journal of the American Association for Cancer Research (2010).

[PMID: 20068073] PubMed


Glioblastoma multiforme (GBM) is the most aggressive human primary brain tumor and is currently incurable. Immunotherapies have the potential to target GBM stem cells, which are resistant to conventional therapies. Human epidermal growth factor receptor 2 (HER2) is a validated immunotherapy target, and we determined if HER2-specific T cells can be generated from GBM patients that will target autologous HER2-positive GBMs and their CD133-positive stem cell compartment.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.